Fetal and neonatal outcomes in intrahepatic cholestasis of pregnancy

Parul Sharma, Bani Sarkar, Bangali Majhi


Background: Intrahepatic cholestasis of pregnancy has been associated with adverse fetal and neonatal outcomes. The objective of this study was to assess the improvement in fetal and neonatal outcomes with timely intervention in pregnant females with intrahepatic cholestasis of pregnancy

Methods: This prospective observational study included 50 patients attending antenatal clinic of the Department of Obstetrics and Gynecology of Dr. RML Hospital, from 1st November 2015 to 31st March 2017, using inclusion and exclusion criteria. History, examination, blood investigations, with ultrasound upper abdomen was done for all the patients. Diagnosed patients were treated accordingly and fetal and neonatal outcomes were studied. The data was analyzed using STATA (version 13.1, Stata Corp 4905 Lakeway Drive College Station, Texas 77845 USA). Comparisons were analyzed using Chi-Square, Student’s t-tests.

Results: In the present study, in view of timely diagnosis and intervention, 82% of the neonates had birth weight >2.5kg. 94% of the total neonates had >7 APGAR at 1min, and 100% of the neonates had >7 APGAR at 5min. No stillbirth was observed in present study group. No NICU admission was observed in the present study.

Conclusions: Patients with intrahepatic cholestasis of pregnancy should be taken with utmost care. With early intervention, the adverse effects on fetus and neonates can be reduced to a significant amount.


APGAR, Fetal, Intrahepatic cholestasis, NICU, neonatal

Full Text:



Joshi D, James A, Quaglia A, Westbrook RH, Heneghan MA. Liver disease in pregnancy. Lancet. 2010;375:594-605.

Lammert F, Marschall HU, Glantz A, Matern S. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol. 2000;33:1012-21.

Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol. 2009;15:2049-66.

Mullally BA, Hansen WF. Intrahepatic cholestasis of pregnancy: review of the literature. Obstet Gynecol Surv. 2002;57(1):47-52.

Kondrackiene J, Kupcinskas L. Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems. World J Gastroenterol. 2008;14(38):5781-8.

Bacq Y, Sentilhes L, Reyes HB, Glantz A, Kondrackiene J, Binder T, et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterol. 2012;143(6):1492-501.

Chappell LC, Gurung V, Seed PT, Chambers J, Williamson C, Thornton JG. Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ. 2012;344:e3799.

Pan C, Perumalswami PV. Pregnancy-related liver diseases. Clin Liver Dis. 2011;15(1):199-208.

Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatol. 2004;40(2):467-74.

Davies MH, da Silva RC, Jones SR, Weaver JB, Elias E. Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid. Gut. 1995;37(4):580-4.

Palma J, Reyes H, Ribalta J, Hernández I, Sandoval L, Almuna R, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol. 1997;27(6):1022-8.

Rook M, Vargas J, Caughey A, Bacchetti P, Rosenthal P, Bull L. Fetal outcomes in pregnancies complicated by intrahepatic cholestasis of pregnancy in a Northern California cohort. PLoS One. 2012;7(3):e28343.

Benjaminov FS, Heathcote J. Liver disease in pregnancy. Am J Gastroenterol. 2004;99:2479-88.

Kondrackiene J, Beuers U, Kupcinskas L: Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterol. 2005;129(3):894-901.

Glantz A, Marschall HU, Lammert F, Mattsson LÅ. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatol. 2005;42(6):1399-405.

Ge X, Xu YQ, Huang SH, Huang K, Mao LJ, Pan WJ, et al. Intrahepatic cholestasis of pregnancy and fetal outcomes: a prospective birth cohort study. Zhonghua Liu Xing Bing Xue Za Zhi. 2016;37(2):187-91.

Türkmen GG, Timur H, Yilmaz Z, Kirbas A, Daglar K, Tokmak A, et al. Effect of intrahepatic cholestasis of pregnancy on maternal serum screening tests. J Neonatal Perinatal Med. 2016;9(4):411-5.

Garcia-Flores J, Cañamares M, Cruceyra M, Garicano A, Espada M, Lopez A, et al. Clinical value of maternal bile Acid quantification in intrahepatic cholestasis of pregnancy as an adverse perinatal outcome predictor. Gynecol Obstet Invest. 2015;79(4):222-8.

Brouwers L, Koster MPH, Page-Christiaens GCML, Kemperman H, Boon J, Evers IM, et al. Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. Am J Obstet Gynecol 2015;212:100.e1-7.

Wikström Shemer E, Marschall HU, Ludvigsson JF, Stephansson O. Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. BJOG. 2013;120:717-23.

Sharma N, Panda S, Santa Singh A. Obstetric outcome during an era of active management for obstetrics cholestasis. J Obstet Gynecol India. 2016;66(1):38-41.